Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Occupational Burnout – Part 1: Who (or What) is Responsible?

This is the first part of a two-part blog post by WorkCare Associate Medical Director Brittany Busse, M.D. It’s no wonder job burnout is trending on social media and being discussed at occupational health and safety conferences. The World Health Organization (WHO) recently expanded on its definition of occupational burnout as a syndrome (not as…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

This is the first part of a two-part blog post by WorkCare Associate Medical Director Brittany Busse, M.D.

It’s no wonder job burnout is trending on social media and being discussed at occupational health and safety conferences.

The World Health Organization (WHO) recently expanded on its definition of occupational burnout as a syndrome (not as a medical condition) in the International Classification of Diseases 11th Revision (ICD-11), the global gold standard for diagnostic information. In ICD-11, the WHO defines job burnout as:

“A syndrome conceptualized as resulting from chronic workplace stress that has not been successfully managed.”

It lists three related characteristics:

  • Feelings of energy depletion or exhaustion
  • Increased mental distance from one’s job, or feelings of negativism or cynicism toward one’s job
  • Reduced professional efficacy

According to a WHO statement: “Burnout refers specifically to phenomena in the occupational context and should not be applied to describe experiences in other areas of life.” In an interesting related development, the organization reports it plans to embark on the development of evidence-based guidelines on mental well-being in the workplace.

Underlying Causes

The underlying causes of occupational burnout symptoms are not well-understood. However, many researchers believe burnout syndrome is related to chronically elevated levels of the adrenal hormone cortisol, which eventually leads to adrenal fatigue and insensitivity of body tissues to cortisol.

Chronically elevated cortisol levels and cortisol insensitivity can lead to immune system and other body system dysfunctions that are associated with the development of conditions ranging from heart disease and stroke, to autoimmune disease and cancer. This suggests that occupational burnout is either a cause of disease or a disease in and of itself.

According to the WHO, other mental health diseases – such as anxiety, depression, and other adjustment and mood disorders – must be ruled out before a diagnosis of burnout can be made, indicating that these other conditions arise organically and cannot necessarily be blamed on occupational stress.

Cost of Burnout

We know that the cost of occupational burnout is high. It is believed to be especially prevalent in certain types of professions, including health care and public safety (e.g., medical, police, fire, emergency response and military personnel).

Among physicians alone, an estimated $4.6 billion in annual costs related to physician turnover and reduced clinical hours may be attributed to burnout in the U.S., according to a study published in Annals of Internal Medicine. Given the risk of occupational burnout among all types of professions, the costs to employers, employees and society, in general, may be incalculable.

Who is Responsible?

Considering that burnout is so costly in terms of financial loss, social consequences and personal well-being, it seems reasonable to ask the question: Whose responsibility is it is to manage an employee’s level of stress?

I answer this question in Part 2 of this blog post. I base my response on the assertion that occupational burnout syndrome is a cumulative trauma injury, and that it is both the employer’s and the employee’s responsibility to work together to prevent and effectively manage burnout symptoms.

To learn more information head to the WorkCare’s website.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512